Abstract | OBJECTIVES:
Rheumatoid arthritis is associated with an increased risk of adverse pregnancy outcomes. TNF inhibitors are effective in the treatment of signs and symptoms of the disease although their safety during pregnancy is debated. METHODS: Two cases of women with rheumatoid arthritis in complete remission of the disease with etanercept who decided to continue the therapy throughout their pregnancy are presented. A longitudinal evaluation of the disease activity showed a satisfactory control and good pregnancy outcomes were obtained. A flare of the disease after delivery was not observed. CONCLUSIONS:
Etanercept seems to be safe during pregnancy and lactation. A good control of the activity of the disease was reported throughout the pregnancy and during puerperium, when a reactivation of rheumatoid arthritis is often observed.
|
Authors | Crescenzio Scioscia, Marco Scioscia, Maria Grazia Anelli, Emanuela Praino, Stefano Bettocchi, Giovanni Lapadula |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2011 Jan-Feb
Vol. 29
Issue 1
Pg. 93-5
ISSN: 0392-856X [Print] Italy |
PMID | 21269575
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Etanercept
|
Topics |
- Adult
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy, physiopathology)
- Etanercept
- Female
- Health Status
- Humans
- Immunoglobulin G
(therapeutic use)
- Infant, Newborn
- Lactation
(drug effects)
- Live Birth
- Pregnancy
- Pregnancy Complications
(drug therapy)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Remission Induction
- Severity of Illness Index
- Young Adult
|